Board Appointment
Oxford BioDynamics Plc announced the appointment of Martin Diggle as a Non-Executive Director, effective April 15, 2026, nominated by its largest shareholder, Vulpes Investment Management. Diggle, co-founder of Vulpes Investment Management and Chairman of the Vulpes Life Sciences fund, brings extensive life sciences and capital markets experience, having served on the boards of several public and private companies. This appointment replaces Stephen Diggle, who stepped down on January 26, 2026.
Select text to share a quote on X · sign in to keep highlights & notes in your OBD notes
Oxford, UK - 15 April 2026 - Oxford BioDynamics Plc (AIM: OBD), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, is pleased to announce the appointment of Martin Diggle as a Non-Executive Director with effect from 15 April 2026.
Martin was nominated by Vulpes Investment Management, the Company's largest shareholder through the Vulpes Testudo fund and the Vulpes Life Sciences fund, replacing Stephen Diggle who stepped down as a Director of the Company on 26 January 2026. Martin is the co-founder of Vulpes Investment Management, and Chairman and director of the Vulpes Life Sciences fund.
Martin has extensive experience in the life sciences sector and has served on the Board of several public and privately listed companies such as Oxford Biomedica, Scancell, Proteome Sciences, Leucid Bio, Chronos Therapeutics and Oxford Endovascular. Prior to Vulpes, he was a Partner and Director of UBS/Brunswick. Before that, he spent 7 years at Morgan Stanley. Martin graduated from the University of Oxford with a Masters in Philosophy, Politics and Economics.
Executive Chairman Iain Ross said: "Martin brings a wealth of capital markets and life sciences expertise to the Board. I am thankful for his and Vulpes' ongoing support towards OBD and look forward to working together."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.